[go: up one dir, main page]

FR3031112B1 - DNA CONSTRUCTION FOR THE TREATMENT OF OCULAR DISEASES - Google Patents

DNA CONSTRUCTION FOR THE TREATMENT OF OCULAR DISEASES Download PDF

Info

Publication number
FR3031112B1
FR3031112B1 FR1463346A FR1463346A FR3031112B1 FR 3031112 B1 FR3031112 B1 FR 3031112B1 FR 1463346 A FR1463346 A FR 1463346A FR 1463346 A FR1463346 A FR 1463346A FR 3031112 B1 FR3031112 B1 FR 3031112B1
Authority
FR
France
Prior art keywords
treatment
ocular diseases
dna construction
dna
construction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1463346A
Other languages
French (fr)
Other versions
FR3031112A1 (en
Inventor
Luc Lebreton
Elodie Touchard
Romain Bern Ard
Karine BIGOT
Cecile Madaras
Francine Behar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EYEVENSYS
Original Assignee
EYEVENSYS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EYEVENSYS filed Critical EYEVENSYS
Priority to FR1463346A priority Critical patent/FR3031112B1/en
Publication of FR3031112A1 publication Critical patent/FR3031112A1/en
Application granted granted Critical
Publication of FR3031112B1 publication Critical patent/FR3031112B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/80—Vectors comprising a special origin of replication system from vertebrates
    • C12N2820/85—Vectors comprising a special origin of replication system from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1463346A 2014-12-24 2014-12-24 DNA CONSTRUCTION FOR THE TREATMENT OF OCULAR DISEASES Active FR3031112B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1463346A FR3031112B1 (en) 2014-12-24 2014-12-24 DNA CONSTRUCTION FOR THE TREATMENT OF OCULAR DISEASES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1463346 2014-12-24
FR1463346A FR3031112B1 (en) 2014-12-24 2014-12-24 DNA CONSTRUCTION FOR THE TREATMENT OF OCULAR DISEASES

Publications (2)

Publication Number Publication Date
FR3031112A1 FR3031112A1 (en) 2016-07-01
FR3031112B1 true FR3031112B1 (en) 2018-05-25

Family

ID=53177575

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1463346A Active FR3031112B1 (en) 2014-12-24 2014-12-24 DNA CONSTRUCTION FOR THE TREATMENT OF OCULAR DISEASES

Country Status (1)

Country Link
FR (1) FR3031112B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3111913A1 (en) * 2020-06-30 2021-12-31 Eyevensys CONSTRUCTION OF DNA FOR THE TREATMENT OF EYE PATHOLOGIES
JP2023548145A (en) * 2020-10-29 2023-11-15 リジェネックスバイオ インコーポレイテッド Vectored TNF-alpha antagonists for ocular indications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004002773T2 (en) * 2003-05-09 2007-08-16 Genentech Inc., San Francisco PEPTIDES THAT BIND TO APO2L (TRAIL) RECEPTORS AND USES THEREOF
KR20050082389A (en) * 2004-02-18 2005-08-23 메덱스젠 주식회사 Pharmaceutical composition for treatment of transplantation rejection comprising concatameric immunoadhesin
WO2006123248A2 (en) * 2005-04-18 2006-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject

Also Published As

Publication number Publication date
FR3031112A1 (en) 2016-07-01

Similar Documents

Publication Publication Date Title
FR25C1001I1 (en) ANTIBODY COMPOSITIONS FOR THE TREATMENT OF TUMORS
EP3359074A4 (en) ELECTROPORATION FOR THE TREATMENT OF OBESITY OR DIABETES
MA45192A (en) ASSOCIATION TREATMENT
MA45539A (en) DIHYDROPYRANOPYRIMIDINES FOR THE TREATMENT OF VIRAL INFECTIONS
MA45481A (en) USE OF EXOSOMES FOR THE TREATMENT OF DISEASES
DK3516060T3 (en) ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF EYE DISEASE
MA47719A (en) ESKETAMINE FOR THE TREATMENT OF DEPRESSION
ME03314B (en) RNA-BASED THERAPY FOR THE TREATMENT OF EYE DISEASES
EP3390634A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
MA41028A (en) METHODS AND FORMULATIONS FOR THE TREATMENT OF VASCULAR EYE PATHOLOGIES
EP3313325A4 (en) IMPLANTABLE SCAFFOLDS FOR THE TREATMENT OF SINUSITIS
DK3364997T5 (en) ASPARTOACYLASE GENE THERAPY FOR THE TREATMENT OF CANAVAN'S DISEASE
EP3233878A4 (en) PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
MA39748A (en) CENICRIVIROC FOR THE TREATMENT OF FIBROSIS
MA44875A (en) COMPOSITIONS FOR THE TREATMENT OF ACID BASIC DISORDERS
EP3393468A4 (en) METHODS FOR THE TREATMENT OF IMMUNODEFICIENT DISEASE
EP3374502A4 (en) METHODS FOR THE TREATMENT OF CORNEAL DYSTROPHIES
MA53568A (en) DRUGS FOR THE TREATMENT OF OPHTHALMIC DISEASES
MA43570A (en) GENE THERAPY TO TREAT FAMILY HYPERCHOLESTEROLEMIA
EP2959903A4 (en) MEDICATION FOR THE TREATMENT OF EYE DISEASE
MA52252A (en) NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA
EP3362065A4 (en) POLYTHERAPY FOR THE TREATMENT OF MALIGNANTS
EP3316887A4 (en) GLS1 INHIBITORS FOR THE TREATMENT OF DISEASES
HUE059387T2 (en) Treatment of Parkinson's disease
MA47395A (en) METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASE

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20160701

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11